Skip to main content
. 2023 Aug 23;83(21):3577–3592. doi: 10.1158/0008-5472.CAN-23-0025

Figure 8.

Figure 8. FAK and YAP inhibition enhances the efficacy of anti-VEGF therapy. A, Schematic representation of HSC/MC38 coinjection subcutaneous tumor models used in B–E. MC38 cells (0.5×106) were subcutaneously injected with or without primary murine HSCs (0.5×106) into C57BL/6 mice. After 7 days, mice were treated with 5-FU+IgG, 5-FU+B20, 5-FU+B20+FAKi, or 5-FU+B20+YAPi (5-FU, 50 mg/kg; B20, 5 mg/kg; FAKi, 5 mg/kg; YAPi, 10 mg/kg; twice a week, 3 weeks). B, Representative images of subcutaneous tumors of mice treated with indicated treatment. C, Relative tumor growth curves (top) and relative tumor volume (bottom) of subcutaneous tumors with indicated treatment (one-way ANOVA; n = 5 per group). D, Representative IHC images of serial sections of subcutaneous tumors of mice with indicated treatment. Scale bar, 100 μm. E, Representative immunofluorescence images (left) showing tumor vessels (stained for CD31) and quantification of vessel density (right) in subcutaneous tumors with indicated treatment. Scale bar, 50 μm (one-way ANOVA; n = 5 per group). Data are graphed as the mean ± SD. ns, not significant; P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001. (A, Created with BioRender.com.)

FAK and YAP inhibition enhances the efficacy of anti-VEGF therapy. A, Schematic representation of HSC/MC38 coinjection subcutaneous tumor models used in B–E. MC38 cells (0.5×106) were subcutaneously injected with or without primary murine HSCs (0.5×106) into C57BL/6 mice. After 7 days, mice were treated with 5-FU+IgG, 5-FU+B20, 5-FU+B20+FAKi, or 5-FU+B20+YAPi (5-FU, 50 mg/kg; B20, 5 mg/kg; FAKi, 5 mg/kg; YAPi, 10 mg/kg; twice a week, 3 weeks). B, Representative images of subcutaneous tumors of mice treated with indicated treatment. C, Relative tumor growth curves (top) and relative tumor volume (bottom) of subcutaneous tumors with indicated treatment (one-way ANOVA; n = 5 per group). D, Representative IHC images of serial sections of subcutaneous tumors of mice with indicated treatment. Scale bar, 100 μm. E, Representative immunofluorescence images (left) showing tumor vessels (stained for CD31) and quantification of vessel density (right) in subcutaneous tumors with indicated treatment. Scale bar, 50 μm (one-way ANOVA; n = 5 per group). Data are graphed as the mean ± SD. ns, not significant; P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001. (A, Created with BioRender.com.)